Vigmed receives first larger order for the arterial catheter SWiTCH

After less than one month of testing the SWiTCH needle protected safety arterial catheter with end-users, one of the major distributors in Europe has placed a first larger order for delivery in October.

 “We are obviously pleased with this order and the positive feedback we are receiving from the market. Short term, this will ensure that we deliver on our monthly sales forecast for October. Even if order levels are modest, we now see four consecutive months of increasing sales," says CEO Finn Ketler. “The initial uptake of SWiTCH indicates that our development team has successfully managed to connect different aspects of the user needs for such products.”

The SWiTCH product offers users a safer method for gaining access to a patient’s radial artery than products currently on the market. The current products are associated with risks of both blood spillage and needlestick injury, both of which are minimised by the SWiTCH needle protected safety catheter. Access to the radial artery for monitoring and blood testing is often needed for critically ill patients or those that are undergoing more complicated surgical procedures.

As the SWiTCH product still is in a market test period and for competitive reasons, the identity of the distributor will not to be named in this press release.

For further information contact:

CEO, Finn Ketler +46 42 600 5311 or Sales Director Europe, Mike Dooley +46 42 600 5317

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market patented, needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed’s share is traded on NASDAQ OMX First North Premier in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

Tags: